Assessment of Cytomegalovirus DNA doubling time and virus-specific T-cell responses in the management of CMV infection in allogeneic hematopoietic stem cell transplant recipients undergoing Letermovir prophylaxis

Bone Marrow Transplant. 2024 Oct;59(10):1480-1482. doi: 10.1038/s41409-024-02376-2. Epub 2024 Jul 20.
No abstract available

Publication types

  • Letter

MeSH terms

  • Acetates* / therapeutic use
  • Adult
  • Aged
  • Allografts
  • Antiviral Agents / therapeutic use
  • Cytomegalovirus Infections* / etiology
  • Cytomegalovirus Infections* / prevention & control
  • Cytomegalovirus*
  • DNA, Viral* / blood
  • Female
  • Hematopoietic Stem Cell Transplantation* / adverse effects
  • Humans
  • Male
  • Middle Aged
  • Quinazolines* / therapeutic use
  • T-Lymphocytes / immunology
  • Transplantation, Homologous

Substances

  • letermovir
  • DNA, Viral
  • Quinazolines
  • Acetates
  • Antiviral Agents